CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Up 391.3% in November

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 7,860,000 shares, a growth of 391.3% from the October 31st total of 1,600,000 shares. Approximately 30.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 63,190,000 shares, the days-to-cover ratio is presently 0.1 days.

CERo Therapeutics Stock Down 4.6 %

NASDAQ:CERO traded down $0.01 during trading hours on Friday, hitting $0.19. The company had a trading volume of 6,488,454 shares, compared to its average volume of 20,695,520. The company has a 50-day moving average of $0.13 and a 200 day moving average of $0.29. CERo Therapeutics has a 1 year low of $0.06 and a 1 year high of $12.80.

Insider Activity

In other news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of CERo Therapeutics stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $0.10, for a total value of $325,000.00. Following the sale, the insider now directly owns 22,620,783 shares of the company’s stock, valued at $2,262,078.30. The trade was a 12.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Stuart M. Sloan sold 532,486 shares of CERo Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $0.10, for a total value of $53,248.60. Following the completion of the sale, the insider now directly owns 21,067,956 shares in the company, valued at $2,106,795.60. This represents a 2.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.00% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.